Di Perri G - Search Results

1

Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.

de Requena DG, Bonora S, Calcagno A, D'Avolio A, Siccardi M, Fontana S, Milia MG, Sciandra M, Garazzino S, Di Garbo A, Baietto L, Trentini L, Di Perri G. de Requena DG, et al. Among authors: di perri g, di garbo a. Antimicrob Agents Chemother. 2008 Mar;52(3):1066-71. doi: 10.1128/AAC.01063-07. Epub 2007 Dec 26. Antimicrob Agents Chemother. 2008. PMID: 18160524 Free PMC article.

2

Quinine-induced blindness reversed by an increase in alpha1-acid glycoprotein level.

Di Perri G, Allegranzi B, Bonora S. Di Perri G, et al. Ann Intern Med. 2002 Feb 19;136(4):339. doi: 10.7326/0003-4819-136-4-200202190-00016. Ann Intern Med. 2002. PMID: 11848734 No abstract available.

3

Tuberculosis and treatment with infliximab.

De Rosa FG, Bonora S, Di Perri G. De Rosa FG, et al. Among authors: di perri g. N Engl J Med. 2002 Feb 21;346(8):623-6. N Engl J Med. 2002. PMID: 11859882 Free article. No abstract available.

4

Alpha 1-acid glycoprotein levels in human immunodeficiency virus-infected subjects on antiretroviral regimens.

Boffito M, Sciole K, Raiteri R, Bonora S, Hoggard PG, Back DJ, Di Perri G. Boffito M, et al. Among authors: di perri g. Drug Metab Dispos. 2002 Jul;30(7):859-60. doi: 10.1124/dmd.30.7.859. Drug Metab Dispos. 2002. PMID: 12132432 No abstract available.

5

Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting.

Boffito M, Bonora S, Raiteri R, Reynolds HE, Hoggard PG, Sinicco A, Back DJ, Di Perri G. Boffito M, et al. Among authors: di perri g. Ther Drug Monit. 2002 Aug;24(4):574-6. doi: 10.1097/00007691-200208000-00021. Ther Drug Monit. 2002. PMID: 12142647 Clinical Trial. No abstract available.

6

The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.

Boffito M, Hoggard PG, Reynolds HE, Bonora S, Meaden ER, Sinicco A, Di Perri G, Back DJ. Boffito M, et al. Among authors: di perri g. Br J Clin Pharmacol. 2002 Sep;54(3):262-8. doi: 10.1046/j.1365-2125.2002.01663.x. Br J Clin Pharmacol. 2002. PMID: 12236846 Free PMC article.

7

Simultaneous determination of rifampicin and efavirenz in plasma.

Boffito M, Tija J, Reynolds HE, Hoggard PG, Bonora S, Di Perri G, Back DJ. Boffito M, et al. Among authors: di perri g. Ther Drug Monit. 2002 Oct;24(5):670-4. doi: 10.1097/00007691-200210000-00015. Ther Drug Monit. 2002. PMID: 12352941

8

Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.

Boffito M, Arnaudo I, Raiteri R, Bonora S, Sinicco A, Di Garbo A, Reynolds HE, Hoggard PG, Back DJ, Di Perri G. Boffito M, et al. Among authors: di perri g, di garbo a. AIDS. 2002 Oct 18;16(15):2081-3. doi: 10.1097/00002030-200210180-00015. AIDS. 2002. PMID: 12370509

9

Lopinavir measurement in pleural effusion in a human immunodeficiency virus type 1-infected patient with kaposi's sarcoma.

Boffito M, Hoggard PG, Back DJ, Bonora S, Maiello A, Lucchini A, Di Perri G. Boffito M, et al. Among authors: di perri g. Antimicrob Agents Chemother. 2002 Nov;46(11):3684-5. doi: 10.1128/AAC.46.11.3684-3685.2002. Antimicrob Agents Chemother. 2002. PMID: 12384393 Free PMC article. No abstract available.

10

Pharmacokinetics of saquinavir co-administered with cimetidine.

Boffito M, Carriero P, Trentini L, Raiteri R, Bonora S, Sinicco A, Reynolds HE, Hoggard PG, Back DJ, Di Perri G. Boffito M, et al. Among authors: di perri g. J Antimicrob Chemother. 2002 Dec;50(6):1081-4. doi: 10.1093/jac/dkf232. J Antimicrob Chemother. 2002. PMID: 12461038

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

718 results

Search Page